Dermatological Diseases
Watch Time: 7 mins

Jonathan A Bernstein, EAACI 2022: Findings from the Phase 2b Extension Study of Ligelizumab in Chronic Spontaneous Urticaria

Published Online: July 28th 2022

Ligelizumab is a monoclonal anti-immunoglobulin (Ig) E antibody that has been investigated in the treatment of chronic spontaneous urticaria. touchIMMUNOLOGY were delighted to speak with Prof. Jonathan A Bernstein (University of Cincinnati; Bernstein Allergy Group & Bernstein Clinical Research Center, Cincinnati, OH, USA) around the aims, design and findings from the phase 2b extension study and the future of ligelizumab after failing to show superiority to omalizumab in this indication.

The abstract ‘Long term control of urticaria disease activity with ligelizumab in patients with chronic spontaneous urticaria: data from the Phase 2b extension study.‘ was presented at EAACI 2022, 1-3 July, 2022.

Questions

  1.     Could you describe the current standard of care for chronic spontaneous urticaria (CSU)? (0:21)
  2.     What is ligelizumab and what was the rationale for its use in CSU? (3:18)
  3.     Could you describe the aims, design and inclusion criteria of the phase 2b extension study? (4:17)
  4.     What were the findings of the study and were these consistent with the core study? (5:26)
  5.     Given the failure of ligelizumab to demonstrate superiority vs omalizumab in the PEARL 1 and PEARL 2 Phase III studies, will the clinical development of ligelizumab continue in this indication? (6:39)

Disclosures: Jonathan Bernstein discloses consulting for Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; receiving grant/ research support from Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; serving on advisory boards for Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; receiving honoraria from Genentech, Novartis, Astra Zeneca, Sanofi Regeneron, Celldex, Escient, Allakos and Amgen; and participating in speaker’s bureaus for Genentech, Novartis, Astra Zeneca and Sanofi Regeneron.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the EAACI Hybrid Congress 2022.

Share this Video
Related Videos In Dermatological Diseases
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72